Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EnWave, Merck enter Research Evaluation Agreement
EnWave has granted Merck an exclusive research license to use its technology and licensed patents for the duration of the evaluation, besides providing an option to obtain an
EnWave has granted Merck an exclusive research license to use its technology and licensed patents for the duration of the evaluation, besides providing an option to obtain an
BioServe will help Fox Chase provide next generation sequencing capabilities as it has developed a new internal laboratory utilizing next-generation sequencing and analysis platforms and novel biological information
The move of the European agency is backed by two large, multi-national, Phase 3 clinical trials that demonstrated the efficacy of Dificlir as oral vancomycin to treat CDI.
microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. Regulus’ expertise in microRNA therapeutics will
Takeda entered into an agreement with Amag to exclusively market Feraheme for all therapeutic applications in Canada. Amag will receive a milestone payment of $3m, upon the first
PLX3397 is an oral agent that selectively co-inhibits three key targets, allows down-modulation of a number of cell types, as well as inhibits Flt3 mutations that are responsible
The company hopes to generate an additional production capacity of more than 150,000kg per year within a year. The expansion of facility will be executed in two phases,
Rozrolimupab is a fully human recombinant anti-RhD monoclonal antibody (mAb) mixture, produced by a single-batch manufacturing strategy designed to capture the natural diversity of the human antibody response
As per the collaboration, Receptos will use its proprietary technology platform to produce high resolution protein crystal structures of the discovery target and thereby help Ono’s structure-based drug
The two bispecific antibodies were developed using the company’s protein conjugation technology, Dock-and-Lock (DNL). The two anti-CD20/CD74 antibodies showed inhibition in the growth of MCL cell lines, as